Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by L T Lam
Loss in McL-1 Function Sensitizes Non-Hodgkin’s Lymphoma Cell Lines to the BCL-2-selective Inhibitor Venetoclax (ABT-199)
Blood Cancer Journal
Oncology
Hematology
Related publications
Inhibition of CHK1 Enhances Cell Death Induced by the BCL-2-Selective Inhibitor ABT-199 in Acute Myeloid Leukemia Cells
Oncotarget
Oncology
Expression Profile of BCL-2, BCL-XL, and McL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models
Molecular Cancer Therapeutics
Cancer Research
Oncology
Metabolic Changes Associated With Metformin Potentiates Anti-BCL-2 Inhibitor, Abt-199, and Cdk9 Inhibitor, Bay-1143572 and Reduces Viability of Lymphoma Cells
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
The BCL2 Inhibitor Venetoclax Is Active in Non-Hodgkin Lymphoma
Cancer Discovery
Oncology
Metabolic Changes Associated With Metformin Potentiates BCL-2 Inhibitor, Venetoclax, and CDK9 Inhibitor, BAY1143572 and Reduces Viability of Lymphoma Cells
Oncotarget
Oncology
ABT-737 Induces Apoptosis in Mantle Cell Lymphoma Cells With a BCL-2high/McL-1low Profile and Synergizes With Other Antineoplastic Agents
Clinical Cancer Research
Cancer Research
Oncology
Glycolysis Inhibition Targets McL-1 to Restore Sensitivity of Lymphoma Cells to ABT-737-induced Apoptosis
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
2-Deoxyglucose-Induced Toxicity Is Regulated by BCL-2 Family Members and Is Enhanced by Antagonizing BCL-2 in Lymphoma Cell Lines
Oncogene
Cancer Research
Genetics
Molecular Biology
The Combination of the Proteasome Inhibitor Bortezomib and the BCL-2 Antisense Molecule Oblimersen Sensitizes Human B-Cell Lymphomas to Cyclophosphamide
Clinical Cancer Research
Cancer Research
Oncology
